Effects of Treatment with Temsirolimus versus Interferon Alpha on Survival of Patients with Metastatic Renal Cell Carcinoma – Single-Center Real-World Experience
Vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors are two main groups of drugs for targeted treatment of metastatic renal cell carcinoma (mRCC). Inhibition of angiogenesis and other growth pathways that are pivotal for tumor progression lead to signific...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sestre Milosrdnice University hospital, Institute of Clinical Medical Research
2024-01-01
|
| Series: | Acta Clinica Croatica |
| Subjects: | |
| Online Access: | https://hrcak.srce.hr/file/481989 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Vascular endothelial growth factor (VEGF) and mammalian target of rapamycin
(mTOR) inhibitors are two main groups of drugs for targeted treatment of metastatic renal cell carcinoma
(mRCC). Inhibition of angiogenesis and other growth pathways that are pivotal for tumor progression
lead to significant improvement of survival in patients with mRCC. The main aim of this study
was to compare the effects of temsirolimus (mTOR inhibitor) and interferon alpha-2a (IFN-alpha-2a)
on overall survival (OS) and progression-free survival (PFS) in patients with T3 stage mRCC who developed
lung metastasis in the first two years after radical nephrectomy. A total of 60 patients diagnosed
with T3 stage renal cancer who developed metastases in the lungs within two years after radical nephrectomy
were included in a prospective study conducted at the Department for Urology, Clinical Center
of Vojvodina and partially retrospective study at the Oncology Institute in Sremska Kamenica. Patients
were divided into two groups consisting of 30 patients according to treatment with temsirolimus or
IFN-alpha. During the first year of treatment, OS of patients treated with temsirolimus was 23.33%,
whereas in patients treated with IFN-alpha it was 16.67%. Median survival in patients treated with
temsirolimus was 9.3 months, whereas in patients treated with IFN-alpha it was 6.9 months, yielding
a statistically significant difference (p=0.028). Patients treated with temsirolimus showed a statistically
significantly longer median PFS compared to patients treated with IFN-alpha (p<0.0085). In conclusion,
temsirolimus therapy had a significantly positive effect on survival in patients with mRCC. Patients
treated with temsirolimus showed significantly longer median survival and median PFS compared to
patients treated with IFN-alpha. |
|---|---|
| ISSN: | 0353-9466 1333-9451 |